RxDoctor Payments Data

Susan Hundley, MD

Family Medicine · Danville, VANPI 1811979529

Payments from drug & device makers

$991in general payments, 2019–2025

Across 66 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$323
  • AbbVie$208
  • Biogen$63
  • Lilly USA, LLC$52
  • Johnson & Johnson$51
  • Medtronic$49
  • plus $244 from 9 others

What the payments were for

  • Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca18$323
AbbVie(2 entities)21$208
Biogen3$63
Lilly USA, LLC4$52
Johnson & Johnson4$51
Medtronic1$49
GSK3$47
Abbott2$37
Mylan Specialty L.p.2$31
Novartis2$29
Amgen2$27
Lundbeck LLC1$21
Pfizer1$19
Dexcom, Inc.1$19
Merck1$14

How this compares

$991 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$2,810
Medicare patients
169
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban90$111,924
JardianceEmpagliflozin74$88,679
EliquisApixaban59$63,517
FarxigaDapagliflozin Propanediol42$60,174
TrulicityDulaglutide40$54,719
OzempicSemaglutide44$52,203
TradjentaLinagliptin38$43,210
Repatha SureclickEvolocumab35$23,084
JanuviaSitagliptin Phosphate14$18,664
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$14,703
LinzessLinaclotide11$12,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,365
RestasisCyclosporine12$9,006
Breo ElliptaFluticasone/Vilanterol14$7,287
Novolog FlexpenInsulin Aspart24$6,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$51$111,92490 claims
PfizerEliquis$19$63,51759 claims
AstraZenecaFarxiga$323$60,17442 claims
Lilly USA, LLCTrulicity$52$54,71940 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$47$21,78742 claims
AbbVieLinzess, Restasis$208$21,24723 claims
MerckJanuvia$14$18,66414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →